{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:19:47Z","timestamp":1794622787826,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20cn016361h0002"],"award-info":[{"award-number":["20cn016361h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21bm0404076h001"],"award-info":[{"award-number":["21bm0404076h001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22cm016381h002"],"award-info":[{"award-number":["22cm016381h002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23ck0106819h001"],"award-info":[{"award-number":["23ck0106819h001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ama121011"],"award-info":[{"award-number":["JP23ama121011"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP26461404"],"award-info":[{"award-number":["JP26461404"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20H03710"],"award-info":[{"award-number":["JP20H03710"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K16799"],"award-info":[{"award-number":["JP19K16799"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K15487"],"award-info":[{"award-number":["JP21K15487"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-00934-1","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T10:38:16Z","timestamp":1742812696000},"page":"595-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant"],"prefix":"10.1038","volume":"6","author":[{"given":"Shunya","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Arimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tansri","family":"Wibowo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6649-6887","authenticated-orcid":false,"given":"Moto","family":"Yaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Tachikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8003-2584","authenticated-orcid":false,"given":"Kentaro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Kusakabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Ichii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asao","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-990X","authenticated-orcid":false,"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-2422","authenticated-orcid":false,"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Tachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9041-2337","authenticated-orcid":false,"given":"Haruhiko","family":"Kishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Igashira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0605-5219","authenticated-orcid":false,"given":"Tsuyoshi","family":"Takiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4504-232X","authenticated-orcid":false,"given":"Toru","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-5288","authenticated-orcid":false,"given":"Yasushi","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-3464","authenticated-orcid":false,"given":"Chihaya","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6119-2032","authenticated-orcid":false,"given":"Ryota","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Oji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4749-7117","authenticated-orcid":false,"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9570-0947","authenticated-orcid":false,"given":"Naoki","family":"Hosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"934_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"934_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","volume":"181","author":"EW Weber","year":"2020","unstructured":"Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181, 46\u201362 (2020).","journal-title":"Cell"},{"key":"934_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"934_CR4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"934_CR5","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1056\/NEJMc2305296","volume":"388","author":"C Quintarelli","year":"2023","unstructured":"Quintarelli, C., Del Bufalo, F. & Locatelli, F. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. Reply. N. Engl. J. Med. 388, 2303\u20132304 (2023).","journal-title":"N. Engl. J. Med."},{"key":"934_CR6","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"934_CR7","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 11, 2748\u20132763 (2021).","journal-title":"Cancer Discov."},{"key":"934_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMsa1311707","volume":"371","author":"L Gragert","year":"2014","unstructured":"Gragert, L. et al. HLA match likelihoods for hematopoietic stem-cell grafts in the US registry. N. Engl. J. Med. 371, 339\u2013348 (2014).","journal-title":"N. Engl. J. Med."},{"key":"934_CR9","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood.2019001212","volume":"134","author":"J Dehn","year":"2019","unstructured":"Dehn, J. et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR. Blood 134, 924\u2013934 (2019).","journal-title":"Blood"},{"key":"934_CR10","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.bbmt.2017.03.006","volume":"23","author":"JN Barker","year":"2017","unstructured":"Barker, J. N. et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol. Blood Marrow Transplant. 23, 882\u2013896 (2017).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"934_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik, L. et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14, 641\u2013650 (2008).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"934_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","volume":"13","author":"CG Kanakry","year":"2016","unstructured":"Kanakry, C. G., Fuchs, E. J. & Luznik, L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat. Rev. Clin. Oncol. 13, 10\u201324 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"934_CR13","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/cncr.30536","volume":"123","author":"DJ Weisdorf","year":"2017","unstructured":"Weisdorf, D. J. et al. Allogeneic transplantation for advanced acute myeloid leukemia: the value of complete remission. Cancer 123, 2025\u20132034 (2017).","journal-title":"Cancer"},{"key":"934_CR14","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1158\/1078-0432.CCR-22-0809","volume":"28","author":"A Nagler","year":"2022","unstructured":"Nagler, A. et al. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: an ALWP\/EBMT analysis. Clin. Cancer Res. 28, 4258\u20134266 (2022).","journal-title":"Clin. Cancer Res."},{"key":"934_CR15","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3324\/haematol.2018.208751","volume":"104","author":"KD Cummins","year":"2019","unstructured":"Cummins, K. D. & Gill, S. Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality? Haematologica 104, 1302\u20131308 (2019).","journal-title":"Haematologica"},{"key":"934_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","volume":"38","author":"M MacKay","year":"2020","unstructured":"MacKay, M. et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat. Biotechnol. 38, 233\u2013244 (2020).","journal-title":"Nat. Biotechnol."},{"key":"934_CR17","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro, F. P. et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia 35, 3282\u20133286 (2021).","journal-title":"Leukemia"},{"key":"934_CR18","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman, D. A. et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 10, e191\u2013e202 (2023).","journal-title":"Lancet Haematol"},{"key":"934_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin, X. et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J. Hematol. Oncol. 15, 88 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"934_CR20","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-20-4543","volume":"27","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute myeloid leukemia. Clin. Cancer Res. 27, 3549\u20133555 (2021).","journal-title":"Clin. Cancer Res."},{"key":"934_CR21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood.2020008221","volume":"138","author":"T Sauer","year":"2021","unstructured":"Sauer, T. et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood 138, 318\u2013330 (2021).","journal-title":"Blood"},{"key":"934_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick, M. B. et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell 40, 494\u2013508.e495 (2022).","journal-title":"Cancer Cell"},{"key":"934_CR23","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood.2020009192","volume":"138","author":"H Jetani","year":"2021","unstructured":"Jetani, H. et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood 138, 1830\u20131842 (2021).","journal-title":"Blood"},{"key":"934_CR24","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","volume":"34","author":"R Myburgh","year":"2020","unstructured":"Myburgh, R. et al. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia 34, 2688\u20132703 (2020).","journal-title":"Leukemia"},{"key":"934_CR25","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","volume":"122","author":"M Casucci","year":"2013","unstructured":"Casucci, M. et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122, 3461\u20133472 (2013).","journal-title":"Blood"},{"key":"934_CR26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","volume":"32","author":"F Perna","year":"2017","unstructured":"Perna, F. et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell 32, 506\u2013519 e505 (2017).","journal-title":"Cancer Cell"},{"key":"934_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01684-0","author":"A Gottschlich","year":"2023","unstructured":"Gottschlich, A. et al. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-023-01684-0 (2023).","journal-title":"Nat. Biotechnol."},{"key":"934_CR28","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s43018-023-00652-6","volume":"4","author":"K Mandal","year":"2023","unstructured":"Mandal, K. et al. Structural surfaceomics reveals an AML-specific conformation of integrin \u03b2(2) as a CAR T cellular therapy target. Nat Cancer 4, 1592\u20131609 (2023).","journal-title":"Nat Cancer"},{"key":"934_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/nm.4431","volume":"23","author":"N Hosen","year":"2017","unstructured":"Hosen, N. et al. The activated conformation of integrin \u03b27 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat. Med. 23, 1436\u20131443 (2017).","journal-title":"Nat. Med."},{"key":"934_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax7706","volume":"14","author":"K Hasegawa","year":"2022","unstructured":"Hasegawa, K. et al. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain. Sci. Transl. Med. 14, eaax7706 (2022).","journal-title":"Sci. Transl. Med."},{"key":"934_CR31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730\u2013737 (1997).","journal-title":"Nat. Med."},{"key":"934_CR32","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","volume":"17","author":"K Tzelepis","year":"2016","unstructured":"Tzelepis, K. et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 17, 1193\u20131205 (2016).","journal-title":"Cell Rep."},{"key":"934_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.iy.12.040194.001355","volume":"12","author":"P Cresswell","year":"1994","unstructured":"Cresswell, P. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12, 259\u2013293 (1994).","journal-title":"Annu. Rev. Immunol"},{"key":"934_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0092-8674(05)80090-X","volume":"75","author":"V Steimle","year":"1993","unstructured":"Steimle, V., Otten, L. A., Zufferey, M. & Mach, B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75, 135\u2013146 (1993).","journal-title":"Cell"},{"key":"934_CR35","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0198-8859(02)00436-6","volume":"63","author":"B Byrne","year":"2002","unstructured":"Byrne, B. et al. Human duodenal epithelial cells constitutively express molecular components of antigen presentation but not costimulatory molecules. Hum. Immunol. 63, 977\u2013986 (2002).","journal-title":"Hum. Immunol."},{"key":"934_CR36","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3389\/fimmu.2018.02144","volume":"9","author":"JE Wosen","year":"2018","unstructured":"Wosen, J. E., Mukhopadhyay, D., Macaubas, C. & Mellins, E. D. Epithelial MHC class II expression and its role in antigen presentation in the gastrointestinal and respiratory tracts. Front. Immunol. 9, 2144 (2018).","journal-title":"Front. Immunol."},{"key":"934_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF00919384","volume":"13","author":"AC Menge","year":"1993","unstructured":"Menge, A. C. & Mestecky, J. Surface expression of secretory component and HLA class II DR antigen on glandular epithelial cells from human endometrium and two endometrial adenocarcinoma cell lines. J. Clin. Immunol. 13, 259\u2013264 (1993).","journal-title":"J. Clin. Immunol."},{"key":"934_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0016-5085(91)90575-6","volume":"100","author":"L Mayer","year":"1991","unstructured":"Mayer, L. et al. Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease. Gastroenterology 100, 3\u201312 (1991).","journal-title":"Gastroenterology"},{"key":"934_CR39","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1182\/blood-2013-11-427781","volume":"124","author":"MD Hazenberg","year":"2014","unstructured":"Hazenberg, M. D. & Spits, H. Human innate lymphoid cells. Blood 124, 700\u2013709 (2014).","journal-title":"Blood"},{"key":"934_CR40","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying, Z. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. 25, 947\u2013953 (2019).","journal-title":"Nat. Med."},{"key":"934_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"934_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu, E. et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32, 520\u2013531 (2018).","journal-title":"Leukemia"},{"key":"934_CR43","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","volume":"106","author":"C Imai","year":"2005","unstructured":"Imai, C., Iwamoto, S. & Campana, D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106, 376\u2013383 (2005).","journal-title":"Blood"},{"key":"934_CR44","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher, M. J. et al. Immune escape of relapsed AML cells after allogeneic transplantation. N. Engl. J. Med. 379, 2330\u20132341 (2018).","journal-title":"N. Engl. J. Med."},{"key":"934_CR45","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"934_CR46","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest."},{"key":"934_CR47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"934_CR48","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"934_CR49","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41375-019-0476-y","volume":"33","author":"T Jain","year":"2019","unstructured":"Jain, T. et al. Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/ refractory B cell non-Hodgkin lymphoma. Leukemia 33, 2540\u20132544 (2019).","journal-title":"Leukemia"},{"key":"934_CR50","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","volume":"4","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 4, 2325\u20132338 (2020).","journal-title":"Blood Adv."},{"key":"934_CR51","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3324\/haematol.2019.219790","volume":"105","author":"B Dholaria","year":"2020","unstructured":"Dholaria, B. et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica 105, 47\u201358 (2020).","journal-title":"Haematologica"},{"key":"934_CR52","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1182\/blood-2014-01-551671","volume":"123","author":"X Zhou","year":"2014","unstructured":"Zhou, X. et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123, 3895\u20133905 (2014).","journal-title":"Blood"},{"key":"934_CR53","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","volume":"10","author":"F Ciceri","year":"2009","unstructured":"Ciceri, F. et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 10, 489\u2013500 (2009).","journal-title":"Lancet Oncol."},{"key":"934_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/tan.12536","volume":"85","author":"N Ikeda","year":"2015","unstructured":"Ikeda, N. et al. Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study. Tissue Antigens 85, 252\u2013259 (2015).","journal-title":"Tissue Antigens"},{"key":"934_CR55","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.humimm.2013.06.025","volume":"74","author":"L Gragert","year":"2013","unstructured":"Gragert, L., Madbouly, A., Freeman, J. & Maiers, M. Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Hum. Immunol. 74, 1313\u20131320 (2013).","journal-title":"Hum. Immunol."},{"key":"934_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02912-x","volume":"9","author":"C Han","year":"2018","unstructured":"Han, C. et al. Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression. Nat. Commun. 9, 468 (2018).","journal-title":"Nat. Commun."},{"key":"934_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.omto.2020.04.004","volume":"17","author":"C Han","year":"2020","unstructured":"Han, C. et al. Polymorphic region-specific antibody for evaluation of affinity-associated profile of chimeric antigen receptor. Mol. Ther. Oncolytics 17, 293\u2013305 (2020).","journal-title":"Mol. Ther. Oncolytics"},{"key":"934_CR58","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0161-5890(99)00083-8","volume":"36","author":"LM Rose","year":"1999","unstructured":"Rose, L. M. et al. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol. Immunol. 36, 789\u2013797 (1999).","journal-title":"Mol. Immunol."},{"key":"934_CR59","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/sj.leu.2400847","volume":"11","author":"F Lacombe","year":"1997","unstructured":"Lacombe, F. et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 11, 1878\u20131886 (1997).","journal-title":"Leukemia"},{"key":"934_CR60","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255\u20131263 (2011).","journal-title":"Blood"},{"key":"934_CR61","doi-asserted-by":"publisher","unstructured":"Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science https:\/\/doi.org\/10.1126\/science.aba1786 (2021).","DOI":"10.1126\/science.aba1786"},{"key":"934_CR62","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","volume":"34","author":"IC Nicholson","year":"1997","unstructured":"Nicholson, I. C. et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol. Immunol. 34, 1157\u20131165 (1997).","journal-title":"Mol. Immunol."},{"key":"934_CR63","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/icb.1991.58","volume":"69","author":"H Zola","year":"1991","unstructured":"Zola, H. et al. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol. Cell Biol. 69, 411\u2013422 (1991).","journal-title":"Immunol. Cell Biol."},{"key":"934_CR64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204269120","volume":"120","author":"T Yokoi","year":"2023","unstructured":"Yokoi, T. et al. Identification of a unique subset of tissue-resident memory CD4(+) T cells in Crohn\u2019s disease. Proc. Natl Acad. Sci. USA 120, e2204269120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00934-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00934-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00934-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T10:02:20Z","timestamp":1745834540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00934-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-00934-1","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"23 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.H. has applied for a patent entitled \u2018Antibody against acute myeloid leukemia\u2019 (PCT\/JP2023\/042029) through the Osaka University Office for University\u2013Industry Collaboration. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}